Strategic partnerships GenomeScan collaborates closely with prestigious clinical centers (Erasmus MC and Leiden University Medical Center) and aims to partner with hospitals, academic institutions, and global pharma/biotech companies to accelerate diagnostics and decision-making in genetic disorders, signaling opportunities for co-development, data-sharing arrangements, and joint studies.

Advancing proteomics access Recent partnership with Olink Holding AB indicates a strategic push to make proteomics high-throughput and blood-efficient, suggesting a potential sales angle for complementary proteomics workflows, sample preparation, and integrated data analysis solutions.

Full-service NGS capacity In-house ISO/IEC 17025 accredited DNA testing facility with rapid 48-hour turnaround and scalable sequencing platforms (NovaSeq 6000, PacBio Sequel) presents opportunities to upsell expanded panels, exome, transcriptomics, and epigenetics services to pharma, biotech, and clinical customers.

Digital project tools Launch of the My Projects portal demonstrates a customer-centric digital engagement layer for project monitoring and secure data access, highlighting potential for subscription-based analytics, data management enhancements, and customer lifecycle expansion.

Global collaboration Existing Nordic collaboration through Leymus Genomics and capacity to serve large clinical and preclinical studies indicates appetite for regional expansion and multi-site studies, presenting cross-sell opportunities for regional CROs, academic consortia, and industry-sponsored trials.